ReviewCurrent neurology and neuroscience reports2019
Update on Restless Legs Syndrome: from Mechanisms to Treatment.
Review in Current neurology and neuroscience reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Effects of Dietary Supplementation in Patients with Restless Legs Syndrome: A Systematic Review.Nutrients · 2024Pooled it
- Pooled it
- Revisiting brain iron deficiency in restless legs syndrome using magnetic resonance imaging.NeuroImage. Clinical · 2022Pooled it
- Large genome-wide association study identifies three novel risk variants for restless legs syndrome.Communications biology · 2020Pooled it
- Therapeutic effects of magnesium and vitamin B6 in alleviating the symptoms of restless legs syndrome: a randomized controlled clinical trial.BMC complementary medicine and therapies · 2022Trial
- Trial
- The role of sleep disorders in the risk for CKD and CKD progression.Clinical kidney journal · 2026Review
- Prevalence and correlates of restless leg syndrome in psychiatric outpatients in Lebanon.Scientific reports · 2025Article
- Hydrotherapy and acupressure in restless legs syndrome: results of a randomized, controlled, three-armed, pilot study (HYDRAC-study).Frontiers in medicine · 2025Article
- Correlates of Restless Legs Syndrome in Older People.Journal of clinical medicine · 2024Article
- Article
- Restless legs syndrome in chronic renal failure patients on dialysis.African health sciences · 2023Article
- Investigation of the relationship between serum irisin level in the idiopathic restless legs syndrome: Could be a marker independent of physical activity?Brain and behavior · 2023Article
- Restless legs syndrome in DNAJC12 deficiency.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Article
- Restless legs syndrome in patients with chronic low back pain.British journal of pain · 2023Article
- Exploring the causes of augmentation in restless legs syndrome.Frontiers in neurology · 2023Review
- Leveraging genetic discoveries for sleep to determine causal relationships with common complex traits.Sleep · 2022Review
- [Identification of restless legs syndrome in polysomnography studies and its association with other variables].Revista de neurologia · 2022Article
- Restless Legs Syndrome Prevalence and Clinical Correlates Among Psychiatric Inpatients: A Multicenter Study.Frontiers in psychiatry · 2022Article
- Diagnostic and Treatment Considerations in Restless Legs Syndrome Complicated by Diabetic Neuropathy.Current diabetes reports · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo provide an overview of the molecular pathways and recent genetic risk loci associated with restless legs syndrome/Willis-Ekbom disease (RLS/WED) and describe the most recent treatment guidelines. RECENT
findingsDiagnostic criteria for RLS/WED now include a fifth criterion to differentiate from RLS/WED mimics. Our understanding of disease pathophysiology has improved, specifically regarding iron regulation in the brain and the role of other pathways such as opioid signaling and brain and spinal cord circuitry may play. Finally, several genetic risk loci have been described, including MEIS1 which is currently considered to be the strongest genetic risk factor for RLS/WED. Treatment guidelines now suggest α2δ ligands such as gabapentin enacarbil should be used as first-line treatment. The current literature focuses on disease pathways as well as the development of animal models based on genetic risk factors for RLS/WED. Updated treatment guidelines expand on first-line treatment options.
Indexed as
Identifiers
31250128What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.